Transgene (OTCPK:TRGN.F) - Cotización, noticias y análisis

Resumen de acción TRGN.F

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

Acerca de la empresa

TRGN.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 70.42%

Análisis de riesgos

Acciones altamente ilíquidas

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Transgene SA

CervoMed

NasdaqCM:CRVO

US$147.4m

YS Biopharma

NasdaqCM:YS

US$139.6m

Genetron Holdings

NasdaqGM:GTH

US$127.3m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$131.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Transgene
Historical stock prices
Current Share Price	€1.62
52 Week High	€2.10
52 Week Low	€1.62
Beta	0.76
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-23.94%
5 Year Change	-51.20%
Change since IPO	-87.14%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	TRGN.F	US Biotechs	Mercado US
7D	0%	-2.5%	-3.2%
1Y	n/a	-3.7%	19.3%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de TRGN.F en comparación con el sector US Biotechs .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de TRGN.F frente al mercado US.

Volatilidad de los precios

Is TRGN.F's price volatile compared to industry and market?
TRGN.F volatility
TRGN.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: TRGN.F no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de TRGN.F en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1979	146	Alessandro Riva	www.transgene.fr

Resumen de fundamentos de Transgene SA

¿Cómo se comparan los beneficios e ingresos de Transgene con su capitalización de mercado?
Estadísticas fundamentales de TRGN.F
Capitalización bursátil	US$149.78m
Beneficios(TTM)	-US$36.50m
Ingresos (TTM)	US$9.73m

15.4x

Ratio precio-ventas (PS)

-4.1x

Ratio precio-beneficio (PE)

¿Está TRGN.F sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TRGN.F
Ingresos	€8.91m
Coste de los ingresos	€30.76m
Beneficio bruto	-€21.86m
Otros gastos	€11.57m
Beneficios	-€33.43m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.33
Margen bruto	-245.38%
Margen de beneficio neto	-375.29%
Ratio deuda/patrimonio	35.7%

¿Cómo se ha desempeñado TRGN.F a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TRGN.F

Recompensas

Análisis de riesgos

Competidores de Transgene SA

NasdaqCM:CRVO

US$147.4m

NasdaqCM:YS

US$139.6m

NasdaqGM:GTH

US$127.3m

NasdaqGS:KPTI

US$131.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Recent updates

Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene SA has completed a Follow-on Equity Offering in the amount of €34.1285 million.

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Transgene SA

15.4x

-4.1x

Beneficios e Ingresos